

To: [REDACTED]@minvws.nl [REDACTED]@minvws.nl
Cc: [REDACTED]@minvws.nl [REDACTED]@minvws.nl
From: [REDACTED] Johnson & Johnson
Sent: Sat 4/24/2021 3:11:17 PM
Subject: Update on Johnson & Johnson COVID-19 Vaccine: single-shot COVID-19 vaccinations to resume in the U.S. for all adults following CDC and FDA decision
Received: Sat 4/24/2021 3:11:30 PM



Dear Minister De Jonge,

Johnson & Johnson announced yesterday evening that vaccinations with the Company's COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S. under Emergency Use Authorization (EUA) following [a decision](#) from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).

The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous scientific evaluation of data relating to a very rare adverse event involving blood clots in combination with low platelet counts (thrombosis with thrombocytopenia) observed within approximately one to two weeks following vaccination.

Johnson & Johnson has updated the EUA Fact Sheets for vaccination providers, recipients and caregivers to include information about the diagnosis and treatment of thrombosis with thrombocytopenia. The Fact Sheets are now available at www.janssencovid19vaccine.com.

Earlier this week, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) also issued a [recommendation](#), confirming the overall benefit-risk profile of the Company's COVID-19 vaccine remains positive.

As the global pandemic continues to devastate communities around the world, we believe a single-shot, easily transportable COVID-19 vaccine with demonstrated protection against multiple variants can help protect the health and safety of people everywhere. We will collaborate with health authorities around the world, to educate healthcare professionals and the public to ensure this very rare event can be identified early and treated effectively.

Johnson & Johnson is committed to providing transparent updates throughout the clinical development process and global rollout of our vaccine. Full details on this news can be found in [our press release](#).

I will continue to keep you updated regarding key developments pertaining to Johnson & Johnson's COVID-19 vaccine.

With best regards,

[REDACTED] [REDACTED]

[REDACTED]

Johnson & Johnson